Literature DB >> 15561879

A subinhibitory concentration of clarithromycin inhibits Mycobacterium avium biofilm formation.

George Carter1, Lowell S Young, Luiz E Bermudez.   

Abstract

Mycobacterium avium causes disseminated infection in immunosuppressed individuals and lung infection in patients with chronic lung diseases. M. avium forms biofilm in the environment and possibly in human airways. Antibiotics with activity against the bacterium could inhibit biofilm formation. Clarithromycin inhibits biofilm formation but has no activity against established biofilm.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15561879      PMCID： PMC529245          DOI： 10.1128/AAC.48.12.4907-4910.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  22 in total

1.  Growth characteristics of atypical mycobacteria in water and their comparative resistance to disinfectants.

Authors:  L A Carson; N J Petersen; M S Favero; S M Aguero
Journal:  Appl Environ Microbiol       Date:  1978-12       Impact factor: 4.792

Review 2.  Nontuberculous mycobacteria in cystic fibrosis.

Authors:  Deborah L Ebert; Kenneth N Olivier
Journal:  Infect Dis Clin North Am       Date:  2002-03       Impact factor: 5.982

3.  Factors influencing numbers of Mycobacterium avium, Mycobacterium intracellulare, and other Mycobacteria in drinking water distribution systems.

Authors:  J O Falkinham; C D Norton; M W LeChevallier
Journal:  Appl Environ Microbiol       Date:  2001-03       Impact factor: 4.792

4.  Telithromycin is active against Mycobacterium avium in mice despite lacking significant activity in standard in vitro and macrophage assays and is associated with low frequency of resistance during treatment.

Authors:  L E Bermudez; C B Inderlied; P Kolonoski; M Wu; P Aralar; L S Young
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

Review 5.  Mycobacterium avium complex pulmonary disease in patients with pre-existing lung disease.

Authors:  Timothy R Aksamit
Journal:  Clin Chest Med       Date:  2002-09       Impact factor: 2.878

6.  Genetic analysis of sliding motility in Mycobacterium smegmatis.

Authors:  J Recht; A Martínez; S Torello; R Kolter
Journal:  J Bacteriol       Date:  2000-08       Impact factor: 3.490

7.  Isolation of two subpopulations of Mycobacterium avium within human macrophages.

Authors:  L E Bermudez; M Wu; E Miltner; C B Inderlied
Journal:  FEMS Microbiol Lett       Date:  1999-09-01       Impact factor: 2.742

8.  Contributions of antibiotic penetration, oxygen limitation, and low metabolic activity to tolerance of Pseudomonas aeruginosa biofilms to ciprofloxacin and tobramycin.

Authors:  Marshall C Walters; Frank Roe; Amandine Bugnicourt; Michael J Franklin; Philip S Stewart
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

9.  A genetic basis for Pseudomonas aeruginosa biofilm antibiotic resistance.

Authors:  Thien-Fah Mah; Betsey Pitts; Brett Pellock; Graham C Walker; Philip S Stewart; George A O'Toole
Journal:  Nature       Date:  2003-11-20       Impact factor: 49.962

10.  Characterization of biofilm formation by clinical isolates of Mycobacterium avium.

Authors:  George Carter; Martin Wu; Daryl C Drummond; Luiz E Bermudez
Journal:  J Med Microbiol       Date:  2003-09       Impact factor: 2.472
View more
  11 in total

1.  Enhancement of biofilm formation by subinhibitory concentrations of macrolides in icaADBC-positive and -negative clinical isolates of Staphylococcus epidermidis.

Authors:  Qian Wang; Feng-Jun Sun; Yao Liu; Li-Rong Xiong; Lin-Li Xie; Pei-Yuan Xia
Journal:  Antimicrob Agents Chemother       Date:  2010-03-15       Impact factor: 5.191

2.  The environment of "Mycobacterium avium subsp. hominissuis" microaggregates induces synthesis of small proteins associated with efficient infection of respiratory epithelial cells.

Authors:  Lmar Babrak; Lia Danelishvili; Sasha J Rose; Tiffany Kornberg; Luiz E Bermudez
Journal:  Infect Immun       Date:  2014-11-24       Impact factor: 3.441

3.  EDP-420, a bicyclolide (bridged bicyclic macrolide), is active against Mycobacterium avium.

Authors:  Luiz E Bermudez; Nima Motamedi; Christopher Chee; Gyulnar Baimukanova; Peter Kolonoski; Clark Inderlied; Priscilla Aralar; Guoqiang Wang; Ly Tam Phan; Lowell S Young
Journal:  Antimicrob Agents Chemother       Date:  2007-02-12       Impact factor: 5.191

4.  Mycobacterium avium ssp. hominissuis biofilm is composed of distinct phenotypes and influenced by the presence of antimicrobials.

Authors:  M McNabe; R Tennant; L Danelishvili; L Young; L E Bermudez
Journal:  Clin Microbiol Infect       Date:  2011-05       Impact factor: 8.067

5.  A Rabbit Model to Study Antibiotic Penetration at the Site of Infection for Nontuberculous Mycobacterial Lung Disease: Macrolide Case Study.

Authors:  Firat Kaya; Jacqueline P Ernest; Katherine LoMauro; Martin Gengenbacher; Abdeldjalil Madani; Wassihun Wedajo Aragaw; Matthew D Zimmerman; Jansy P Sarathy; Nadine Alvarez; Isaac Daudelin; Han Wang; Faye Lanni; Danielle M Weiner; Laura E Via; Clifton E Barry; Kenneth N Olivier; Thomas Dick; Brendan K Podell; Radojka M Savic; Véronique Dartois
Journal:  Antimicrob Agents Chemother       Date:  2022-01-31       Impact factor: 5.938

6.  Differential antibiotic susceptibility of Mycobacterium abscessus variants in biofilms and macrophages compared to that of planktonic bacteria.

Authors:  Rebecca Greendyke; Thomas F Byrd
Journal:  Antimicrob Agents Chemother       Date:  2008-03-31       Impact factor: 5.191

Review 7.  NTM drug discovery: status, gaps and the way forward.

Authors:  Mu-Lu Wu; Dinah B Aziz; Véronique Dartois; Thomas Dick
Journal:  Drug Discov Today       Date:  2018-04-07       Impact factor: 7.851

8.  Treatment outcome of combination therapy including clarithromycin for Mycobacterium avium complex pulmonary disease.

Authors:  Eun Young Kim; Su Young Chi; In Jae Oh; Kyu Sik Kim; Yu Il Kim; Sung Chul Lim; Young Chul Kim; Yong Soo Kwon
Journal:  Korean J Intern Med       Date:  2011-03-02       Impact factor: 2.884

9.  Why is long-term therapy required to cure tuberculosis?

Authors:  Lynn E Connolly; Paul H Edelstein; Lalita Ramakrishnan
Journal:  PLoS Med       Date:  2007-03       Impact factor: 11.069

10.  Biofilm Formation and Antibiotic Resistance Phenotype of Helicobacter pylori Clinical Isolates.

Authors:  Kartika Afrida Fauzia; Muhammad Miftahussurur; Ari Fahrial Syam; Langgeng Agung Waskito; Dalla Doohan; Yudith Annisa Ayu Rezkitha; Takashi Matsumoto; Vo Phuoc Tuan; Junko Akada; Hideo Yonezawa; Shigeru Kamiya; Yoshio Yamaoka
Journal:  Toxins (Basel)       Date:  2020-07-24       Impact factor: 4.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.